166.00 -0.06 (-0.04%)
After hours: 4:16PM EST
|Bid||0.00 x 200|
|Ask||0.00 x 200|
|Day's Range||165.10 - 168.79|
|52 Week Range||146.80 - 179.84|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||58.62|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||1.88 (1.10%)|
|1y Target Est||187.88|
GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.
In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings.
For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.
TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
Stryker (SYK) has completed the previously announced acquisition of K2M Group Holdings, Inc., a global leader of complex spine and minimally invasive solutions. "K2M's broad product portfolio and robust pipeline complement Stryker’s leadership in the spine and neurotechnology markets," said Spencer S. Stiles, Group President, Neurotechnology, Instruments and Spine.